176 related articles for article (PubMed ID: 21155012)
1. Irinotecan-involved regimens for advanced gastric cancer: a pooled-analysis of clinical trials.
Wang DL; Gu DY; Huang HY; Xu Z; Chen JF
World J Gastroenterol; 2010 Dec; 16(46):5889-94. PubMed ID: 21155012
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy with or without irinotecan in patients with advanced or recurrent gastric cancer: a meta-analysis of randomized controlled trials.
Zeng C; Zhou H; Wei Y; Wang L; Xie H; Yao W
Chin Med J (Engl); 2014; 127(5):951-6. PubMed ID: 24571893
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy for advanced gastric cancer.
Wagner AD; Unverzagt S; Grothe W; Kleber G; Grothey A; Haerting J; Fleig WE
Cochrane Database Syst Rev; 2010 Mar; (3):CD004064. PubMed ID: 20238327
[TBL] [Abstract][Full Text] [Related]
4. Meta-analysis of two randomized phase III trials (TCOG GI-0801 and ECRIN TRICS) of biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer.
Nishikawa K; Koizumi W; Tsuburaya A; Yamanaka T; Morita S; Fujitani K; Akamaru Y; Shimada K; Hosaka H; Nakayama N; Tsujinaka T; Sakamoto J
Gastric Cancer; 2020 Jan; 23(1):160-167. PubMed ID: 31309387
[TBL] [Abstract][Full Text] [Related]
5. Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials.
Mitry E; Douillard JY; Van Cutsem E; Cunningham D; Magherini E; Mery-Mignard D; Awad L; Rougier P
Ann Oncol; 2004 Jul; 15(7):1013-7. PubMed ID: 15205193
[TBL] [Abstract][Full Text] [Related]
6. [Irinotecan (CPT-11) therapy for advanced gastric cancer].
Sakata Y
Nihon Rinsho; 2001 Apr; 59 Suppl 4():386-92. PubMed ID: 11424411
[No Abstract] [Full Text] [Related]
7. Platinum-based versus non-platinum-based chemotherapy as first line treatment of inoperable, advanced gastric adenocarcinoma: a meta-analysis.
Chen WW; Wang F; Xu RH
PLoS One; 2013; 8(7):e68974. PubMed ID: 23874831
[TBL] [Abstract][Full Text] [Related]
8. CPT-11 in gastrointestinal cancer.
Bleiberg H
Eur J Cancer; 1999 Mar; 35(3):371-9. PubMed ID: 10448285
[TBL] [Abstract][Full Text] [Related]
9. Survival prolongation after treatment failure of first-line chemotherapy in patients with advanced gastric cancer: combined analysis of the Japan Clinical Oncology group trials JCOG9205 and JCOG9912.
Takashima A; Boku N; Kato K; Nakamura K; Mizusawa J; Fukuda H; Shirao K; Shimada Y; Ohtsu A
Gastric Cancer; 2014; 17(3):522-8. PubMed ID: 24162387
[TBL] [Abstract][Full Text] [Related]
10. Overall survival benefits for irinotecan-containing regimens as first-line treatment for advanced gastric cancer: an updated meta-analysis of ten randomized controlled trials.
Qi WX; Shen Z; Lin F; Sun YJ; Min DL; Tang LN; He AN; Yao Y
Int J Cancer; 2013 Jan; 132(2):E66-73. PubMed ID: 22890856
[TBL] [Abstract][Full Text] [Related]
11. Clinical trials of irinotecan hydrochloride (CPT, campto injection, topotecin injection) in Japan.
Saijo N
Ann N Y Acad Sci; 1996 Dec; 803():292-305. PubMed ID: 8993523
[TBL] [Abstract][Full Text] [Related]
12. Irinotecan-containing doublet treatment versus irinotecan monotherapy as second-line choice for advanced gastric cancer.
Yang L; Jiang X; Yan H; Li Y; Zhen H; Chang B; Kariminia S; Li Q
BMC Gastroenterol; 2018 Apr; 18(1):43. PubMed ID: 29609559
[TBL] [Abstract][Full Text] [Related]
13. Irinotecan Monotherapy Versus Irinotecan-Based Combination as Second-Line Chemotherapy in Advanced Gastric Cancer: A Meta-Analysis.
Cho YH; Yoon SY; Kim SN
Cancer Res Treat; 2017 Jan; 49(1):255-262. PubMed ID: 27188198
[TBL] [Abstract][Full Text] [Related]
14. Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy: TRICS trial.
Nishikawa K; Fujitani K; Inagaki H; Akamaru Y; Tokunaga S; Takagi M; Tamura S; Sugimoto N; Shigematsu T; Yoshikawa T; Ishiguro T; Nakamura M; Morita S; Miyashita Y; Tsuburaya A; Sakamoto J; Tsujinaka T
Eur J Cancer; 2015 May; 51(7):808-16. PubMed ID: 25797356
[TBL] [Abstract][Full Text] [Related]
15. Second-line systemic therapy for metastatic colorectal cancer.
Mocellin S; Baretta Z; Roqué I Figuls M; Solà I; Martin-Richard M; Hallum S; Bonfill Cosp X
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD006875. PubMed ID: 28128439
[TBL] [Abstract][Full Text] [Related]
16. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial.
Hironaka S; Ueda S; Yasui H; Nishina T; Tsuda M; Tsumura T; Sugimoto N; Shimodaira H; Tokunaga S; Moriwaki T; Esaki T; Nagase M; Fujitani K; Yamaguchi K; Ura T; Hamamoto Y; Morita S; Okamoto I; Boku N; Hyodo I
J Clin Oncol; 2013 Dec; 31(35):4438-44. PubMed ID: 24190112
[TBL] [Abstract][Full Text] [Related]
17. A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy.
Sym SJ; Hong J; Park J; Cho EK; Lee JH; Park YH; Lee WK; Chung M; Kim HS; Park SH; Shin DB
Cancer Chemother Pharmacol; 2013 Feb; 71(2):481-8. PubMed ID: 23192279
[TBL] [Abstract][Full Text] [Related]
18. [Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group].
Futatsuki K; Wakui A; Nakao I; Sakata Y; Kambe M; Shimada Y; Yoshino M; Taguchi T; Ogawa N
Gan To Kagaku Ryoho; 1994 Jun; 21(7):1033-8. PubMed ID: 8210254
[TBL] [Abstract][Full Text] [Related]
19. Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysis.
Kim HS; Kim HJ; Kim SY; Kim TY; Lee KW; Baek SK; Kim TY; Ryu MH; Nam BH; Zang DY
Ann Oncol; 2013 Nov; 24(11):2850-4. PubMed ID: 23942775
[TBL] [Abstract][Full Text] [Related]
20. Palliative chemotherapy for advanced gastric cancer.
Wöhrer SS; Raderer M; Hejna M
Ann Oncol; 2004 Nov; 15(11):1585-95. PubMed ID: 15520058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
